Cargando…

The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis

INTRODUCTION: The diagnosis, management, and treatment for hepatitis C virus (HCV) infection (the “HCV care continuum”) have improved in recent years. People who use drugs (PWUD) have a prevalence of HCV infection from 30 to 70 %, yet rates of testing, engagement in care, and treatment for HCV are d...

Descripción completa

Detalles Bibliográficos
Autores principales: Reed, Jennifer R., Jordan, Ashly E., Perlman, David C., Smith, Daniel J., Hagan, Holly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940695/
https://www.ncbi.nlm.nih.gov/pubmed/27401499
http://dx.doi.org/10.1186/s13643-016-0293-6
_version_ 1782442182122143744
author Reed, Jennifer R.
Jordan, Ashly E.
Perlman, David C.
Smith, Daniel J.
Hagan, Holly
author_facet Reed, Jennifer R.
Jordan, Ashly E.
Perlman, David C.
Smith, Daniel J.
Hagan, Holly
author_sort Reed, Jennifer R.
collection PubMed
description INTRODUCTION: The diagnosis, management, and treatment for hepatitis C virus (HCV) infection (the “HCV care continuum”) have improved in recent years. People who use drugs (PWUD) have a prevalence of HCV infection from 30 to 70 %, yet rates of testing, engagement in care, and treatment for HCV are disproportionately low compared to other populations. Delineating the progression of PWUD through the steps in the HCV care continuum in the USA is important in informing efforts to improve HCV outcomes among PWUD. METHODS/DESIGN: Scientific databases will be searched using a comprehensive automated search strategy; gray literature and reference lists will be manually searched. Eligible reports will provide original research data related to the HCV care continuum in the USA including proportions of PWUD engaging in the following discrete steps: screening/testing, engagement in care (including receiving an HCV clinical assessment), treatment initiation and completion, and rates of those with successful HCV treatment. A quality-rating tool will be developed to ascertain the level of bias (including selection bias) in each report, and a quality score will be assigned to each eligible report. A tool adapted from the Pragmatic Explanatory Continuum Indicator Summary-2 instrument will be developed to assess the extent to which an included report reflects an effectiveness or efficacy study design. Pooled estimates and measures of association will be calculated using random effects models, and heterogeneity will be assessed at each stage of data synthesis. DISCUSSION: Through this review, we hope to quantify the proportion of PWUD at each progressive step and to help identify key individual, social, and structural points of leakage in the HCV care continuum for PWUD. In meeting these objectives, we will identify predictors to progress along the HCV care continuum, which can be used to inform policy to directly improve HCV care for PWUD. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42016034113 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13643-016-0293-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4940695
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49406952016-07-13 The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis Reed, Jennifer R. Jordan, Ashly E. Perlman, David C. Smith, Daniel J. Hagan, Holly Syst Rev Protocol INTRODUCTION: The diagnosis, management, and treatment for hepatitis C virus (HCV) infection (the “HCV care continuum”) have improved in recent years. People who use drugs (PWUD) have a prevalence of HCV infection from 30 to 70 %, yet rates of testing, engagement in care, and treatment for HCV are disproportionately low compared to other populations. Delineating the progression of PWUD through the steps in the HCV care continuum in the USA is important in informing efforts to improve HCV outcomes among PWUD. METHODS/DESIGN: Scientific databases will be searched using a comprehensive automated search strategy; gray literature and reference lists will be manually searched. Eligible reports will provide original research data related to the HCV care continuum in the USA including proportions of PWUD engaging in the following discrete steps: screening/testing, engagement in care (including receiving an HCV clinical assessment), treatment initiation and completion, and rates of those with successful HCV treatment. A quality-rating tool will be developed to ascertain the level of bias (including selection bias) in each report, and a quality score will be assigned to each eligible report. A tool adapted from the Pragmatic Explanatory Continuum Indicator Summary-2 instrument will be developed to assess the extent to which an included report reflects an effectiveness or efficacy study design. Pooled estimates and measures of association will be calculated using random effects models, and heterogeneity will be assessed at each stage of data synthesis. DISCUSSION: Through this review, we hope to quantify the proportion of PWUD at each progressive step and to help identify key individual, social, and structural points of leakage in the HCV care continuum for PWUD. In meeting these objectives, we will identify predictors to progress along the HCV care continuum, which can be used to inform policy to directly improve HCV care for PWUD. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42016034113 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13643-016-0293-6) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-11 /pmc/articles/PMC4940695/ /pubmed/27401499 http://dx.doi.org/10.1186/s13643-016-0293-6 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Protocol
Reed, Jennifer R.
Jordan, Ashly E.
Perlman, David C.
Smith, Daniel J.
Hagan, Holly
The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis
title The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis
title_full The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis
title_fullStr The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis
title_full_unstemmed The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis
title_short The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis
title_sort hcv care continuum among people who use drugs: protocol for a systematic review and meta-analysis
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940695/
https://www.ncbi.nlm.nih.gov/pubmed/27401499
http://dx.doi.org/10.1186/s13643-016-0293-6
work_keys_str_mv AT reedjenniferr thehcvcarecontinuumamongpeoplewhousedrugsprotocolforasystematicreviewandmetaanalysis
AT jordanashlye thehcvcarecontinuumamongpeoplewhousedrugsprotocolforasystematicreviewandmetaanalysis
AT perlmandavidc thehcvcarecontinuumamongpeoplewhousedrugsprotocolforasystematicreviewandmetaanalysis
AT smithdanielj thehcvcarecontinuumamongpeoplewhousedrugsprotocolforasystematicreviewandmetaanalysis
AT haganholly thehcvcarecontinuumamongpeoplewhousedrugsprotocolforasystematicreviewandmetaanalysis
AT reedjenniferr hcvcarecontinuumamongpeoplewhousedrugsprotocolforasystematicreviewandmetaanalysis
AT jordanashlye hcvcarecontinuumamongpeoplewhousedrugsprotocolforasystematicreviewandmetaanalysis
AT perlmandavidc hcvcarecontinuumamongpeoplewhousedrugsprotocolforasystematicreviewandmetaanalysis
AT smithdanielj hcvcarecontinuumamongpeoplewhousedrugsprotocolforasystematicreviewandmetaanalysis
AT haganholly hcvcarecontinuumamongpeoplewhousedrugsprotocolforasystematicreviewandmetaanalysis